Krystal Biotech Inc.

AI Score

XX

Unlock

175.79
-4.51 (-2.50%)
At close: Apr 01, 2025, 3:23 PM

Krystal Biotech Statistics

Share Statistics

Krystal Biotech has 28.81M shares outstanding. The number of shares has increased by 0.87% in one year.

Shares Outstanding 28.81M
Shares Change (YoY) 0.87%
Shares Change (QoQ) 0.16%
Owned by Institutions (%) 96.61%
Shares Floating 24.62M
Failed to Deliver (FTD) Shares 50
FTD / Avg. Volume 0.02%

Short Selling Information

The latest short interest is 3.25M, so 11.31% of the outstanding shares have been sold short.

Short Interest 3.25M
Short % of Shares Out 11.31%
Short % of Float 13.37%
Short Ratio (days to cover) 10.79

Valuation Ratios

The PE ratio is 50.24 and the forward PE ratio is 23.58. Krystal Biotech's PEG ratio is 0.07.

PE Ratio 50.24
Forward PE 23.58
PS Ratio 15.42
Forward PS 3.8
PB Ratio 4.73
P/FCF Ratio 37.58
PEG Ratio 0.07
Financial Ratio History

Enterprise Valuation

Krystal Biotech Inc. has an Enterprise Value (EV) of 3.02B.

EV / Earnings 33.86
EV / Sales 10.39
EV / EBITDA 27.46
EV / EBIT 45.95
EV / FCF 25.33

Financial Position

The company has a current ratio of 7.28, with a Debt / Equity ratio of 0.01.

Current Ratio 7.28
Quick Ratio 7.02
Debt / Equity 0.01
Total Debt / Capitalization 0.76
Cash Flow / Debt 17
Interest Coverage 0

Financial Efficiency

Return on equity (ROE) is 0.09% and return on capital (ROIC) is 6.44%.

Return on Equity (ROE) 0.09%
Return on Assets (ROA) 0.08%
Return on Capital (ROIC) 6.44%
Revenue Per Employee $1,056,418.18
Profits Per Employee $324,214.55
Employee Count 275
Asset Turnover 0.28
Inventory Turnover 0.76

Taxes

Income Tax 6.2M
Effective Tax Rate 0.06

Stock Price Statistics

The stock price has increased by 2.43% in the last 52 weeks. The beta is 0.87, so Krystal Biotech's price volatility has been higher than the market average.

Beta 0.87
52-Week Price Change 2.43%
50-Day Moving Average 171.37
200-Day Moving Average 179.66
Relative Strength Index (RSI) 49.24
Average Volume (20 Days) 264.11K

Income Statement

In the last 12 months, Krystal Biotech had revenue of 290.51M and earned 89.16M in profits. Earnings per share was 3.12.

Revenue 290.51M
Gross Profit 270.45M
Operating Income 65.69M
Net Income 89.16M
EBITDA 109.91M
EBIT 65.69M
Earnings Per Share (EPS) 3.12
Full Income Statement

Balance Sheet

The company has 344.87M in cash and 7.26M in debt, giving a net cash position of 337.6M.

Cash & Cash Equivalents 344.87M
Total Debt 7.26M
Net Cash 337.6M
Retained Earnings -180.67M
Total Assets 1.06B
Working Capital 640.05M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 123.42M and capital expenditures -4.24M, giving a free cash flow of 119.18M.

Operating Cash Flow 123.42M
Capital Expenditures -4.24M
Free Cash Flow 119.18M
FCF Per Share 4.17
Full Cash Flow Statement

Margins

Gross margin is 93.09%, with operating and profit margins of 22.61% and 30.69%.

Gross Margin 93.09%
Operating Margin 22.61%
Pretax Margin 32.82%
Profit Margin 30.69%
EBITDA Margin 37.83%
EBIT Margin 22.61%
FCF Margin 41.02%

Dividends & Yields

KRYS does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield 1.73%
FCF Yield 2.29%
Dividend Details

Analyst Forecast

The average price target for KRYS is $218, which is 20.9% higher than the current price. The consensus rating is "Buy".

Price Target $218
Price Target Difference 20.9%
Analyst Consensus Buy
Analyst Count 7
Stock Forecasts

Scores

Altman Z-Score 29.89
Piotroski F-Score 6